Mefloquine- Artesunate — Competitive Intelligence Brief

Mefloquine- Artesunate (Mefloquine- Artesunate) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial combination. Area: Infectious Disease.

marketed Antimalarial combination Parasite heme detoxification pathway; artemisinin-iron adducts generating reactive oxygen species Infectious Disease Small molecule

Target snapshot

Mefloquine- Artesunate (Mefloquine- Artesunate) — Centers for Disease Control and Prevention. Mefloquine and artesunate work synergistically to kill malaria parasites through distinct mechanisms: mefloquine disrupts parasite membrane function while artesunate generates reactive oxygen species that damage parasite proteins and DNA.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Mefloquine- Artesunate TARGET	Mefloquine- Artesunate	Centers for Disease Control and Prevention	marketed	Antimalarial combination	Parasite heme detoxification pathway; artemisinin-iron adducts generating reactive oxygen species
arthemether + lumefantrine	arthemether + lumefantrine	Sanofi	marketed	Antimalarial combination	Plasmodium falciparum heme detoxification pathway; artemisinin-derived endoperoxide bridge
Artesunate plus Amodiaquine	Artesunate plus Amodiaquine	Bernhard Nocht Institute for Tropical Medicine	marketed	Antimalarial combination therapy	Plasmodium falciparum (multiple parasite targets including heme detoxification pathway and DNA synthesis)
Coadministered Artesunate plus Amodiaquine	Coadministered Artesunate plus Amodiaquine	Professor Anders Björkman	marketed	Antimalarial combination therapy	Plasmodium falciparum heme metabolism and protein synthesis
Artemether, Lumefantrine Drug Combination	Artemether, Lumefantrine Drug Combination	University of Yaounde 1	marketed	Antimalarial combination	Plasmodium falciparum heme and mitochondrial function
Sulfadoxine-pyrimethamine plus artesunate	Sulfadoxine-pyrimethamine plus artesunate	London School of Hygiene and Tropical Medicine	marketed	Antimalarial combination	Dihydrofolate reductase, dihydropteroate synthase (sulfadoxine-pyrimethamine); mitochondrial electron transport (artesunate)
Artesunate + Amodiaquine	Artesunate + Amodiaquine	Professor Anders Björkman	marketed	Antimalarial combination	Plasmodium falciparum hemoglobin metabolism and DNA synthesis

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial combination class)

1. Centers for Disease Control and Prevention · 4 drugs in this class
2. Armed Forces Research Institute of Medical Sciences, Thailand · 4 drugs in this class
3. London School of Hygiene and Tropical Medicine · 3 drugs in this class
4. Sanofi · 2 drugs in this class
5. Menzies School of Health Research · 2 drugs in this class
6. Fundação de Medicina Tropical Dr. Heitor Vieira Dourado · 1 drug in this class
7. Epicentre · 1 drug in this class
8. Jhpiego · 1 drug in this class
9. Charite University, Berlin, Germany · 1 drug in this class
10. Ifakara Health Institute · 1 drug in this class